Efficacy News and Research

RSS
More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare 2010 adjusted earnings per share increase 16% to $1.84

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data for treatment of hemophilia B

Losartan improves effectiveness of nanotherapeutics against cancer

Losartan improves effectiveness of nanotherapeutics against cancer

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Inspiration presents IB1001 PK data at European haemophilia congress

Inspiration presents IB1001 PK data at European haemophilia congress

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix closes $14 million Series D financing round

Positive results from Factor IX-CTP comparative study in hemophilic mice

Positive results from Factor IX-CTP comparative study in hemophilic mice

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

FDA approves FSS's FlexStent system IDE for OPEN Trial

FDA approves FSS's FlexStent system IDE for OPEN Trial

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.